The changing opioid crisis: development, challenges and opportunities

Nora D Volkow, Carlos Blanco, Nora D Volkow, Carlos Blanco

Abstract

The current opioid epidemic is one of the most severe public health crisis in US history. Responding to it has been difficult due to its rapidly changing nature and the severity of its associated outcomes. This review examines the origin and evolution of the crisis, the pharmacological properties of opioids, the neurobiology of opioid use and opioid use disorder (OUD), medications for opioid use disorder (MOUD), and existing and promising approaches to prevention. The results of the review indicate that the opioid epidemic is a complex, evolving phenomenon that involves neurobiological vulnerabilities and social determinants of health. Successfully addressing the epidemic will require advances in basic science, development of more acceptable and effective treatments, and implementation of public health approaches, including prevention. The advances achieved in addressing the current crisis should also serve to advance the science and treatment of other substance use disorders.

Conflict of interest statement

Conflict of Interest: The authors have no competing financial interests in relation to the work described in this manuscript.

Figures

Figure 1.
Figure 1.
The circuitry of opioid use disorder (reprinted with permission from: George O, Koob GF. Control of craving by the prefrontal cortex. Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4165-4166

References

    1. Compton WM JC, Baldwin G, Harding F, Blanco C, Wargo EM. Using Prevention Science Principles to Address the U.S. Opioid Crisis. AJPH, in press 2016.
    1. Han B, Compton WM, Blanco C, Jones CM. Correlates of Prescription Opioid Use, Misuse, Use Disorders, and Motivations for Misuse Among US Adults. The Journal of clinical psychiatry 2018; 79(5).
    1. Olfson M, Crystal S, Wall M, Wang S, Liu S, Blanco C. Causes of death after nonfatal opioid overdose. JAMA Psychiatry 2018.
    1. Olfson M, Wall M, Wang S, Crystal S, Blanco C. Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug and alcohol dependence 2018; 190: 112–119.
    1. Pincus HA BC. The Opioid Crisis in America: An Overview In: Confronting Our Nation’s Opioid Crisis, A Report of the Aspen Health Strategy Group. The Aspen Institute; 2017: 23–46.
    1. Medicine Io. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. The National Academies Press; 2011.
    1. Addiction Rare in Patients Treated with Narcotics. New England Journal of Medicine 1980; 302(2): 123–123.
    1. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015; 156(4): 569–576.
    1. Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. Psychological medicine 2012; 42(6): 1261–1272.
    1. Blanco C, Alderson D, Ogburn E, Grant BF, Nunes EV, Hatzenbuehler ML et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug and alcohol dependence 2007; 90(2-3): 252–260.
    1. Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J et al. Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States. The Journal of clinical psychiatry 2016; 77(6): 772–780.
    1. Han B, Compton WM, Jones CM, Cai R. Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. Jama 2015; 314(14): 1468–1478.
    1. Mars SG, Fessel JN, Bourgois P, Montero F, Karandinos G, Ciccarone D. Heroin-related overdose: The unexplored influences of markets, marketing and source-types in the United States. Social science & medicine (1982) 2015; 140: 44–53.
    1. Unick G, Rosenblum D, Mars S, Ciccarone D. The relationship between US heroin market dynamics and heroin-related overdose, 1992-2008. Addiction (Abingdon, England) 2014; 109(11): 1889–1898.
    1. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. , 2013, Accessed Date Accessed 2013 Accessed.
    1. Compton WM, Jones CM, Baldwin GT. Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. The New England Journal of Medicine 2016; 374(2): 154–163.
    1. Drug overdose deaths in the United States, 1999–2017. 2018, Accessed Date Accessed 2018 Accessed.
    1. Jones CM, Einstein EB, Compton WM. Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016Letters. Jama 2018; 319(17): 1819–1821.
    1. Frank RG, Pollack HA. Addressing the Fentanyl Threat to Public Health. The New England Journal of Medicine 2017; 376(7): 605–607.
    1. Suzuki J, El-Haddad S. A review: Fentanyl and non-pharmaceutical fentanyls. Drug and alcohol dependence 2017; 171: 107–116.
    1. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annual review of neuroscience 1984; 7: 223–255.
    1. Pattinson KT. Opioids and the control of respiration. British journal of anaesthesia 2008; 100(6): 747–758.
    1. Elliott JA SH. Handbook of Acute Pain Management. CRC Press: 73–109.
    1. Foley KM. The treatment of cancer pain. The New England Journal of Medicine 1985; 313(2): 84–95.
    1. Foley KM, Inturrisi CE. Analgesic drug therapy in cancer pain: principles and practice. The Medical clinics of North America 1987; 71(2): 207–232.
    1. Freye E LJ. Opioids in medicine. A comprehensive review on the mode of action and the use of analgesics in different clinical pain studies. Springer; 2008; Dordrecht, The Netherlands.
    1. Pharmacists TASoH-S. Fentanyl, Fentanyl Citrate, Fentanyl Hydrochloride. 2018.
    1. Reisine T PG. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE. Goodman & Gilman’s The pharmacological basis of therapeutics. 1996: 521–556.
    1. Smith H PS. Pain and Chemical Dependency. Oxford University Press, New York, NY: 183–202.
    1. Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain syndromes. Pain physician 2011; 14(4): E343–360.
    1. Cai NS, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J et al. Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids. The Journal of clinical investigation 2019; 130.
    1. Ling GS, Paul D, Simantov R, Pasternak GW. Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life sciences 1989; 45(18): 1627–1636.
    1. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008; 154(2): 384–396.
    1. Rich MM, Wenner P. Sensing and expressing homeostatic synaptic plasticity. Trends in neurosciences 2007; 30(3): 119–125.
    1. Xu J, Lu Z, Xu M, Pan L, Deng Y, Xie X et al. A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the mu opioid receptor gene OPRM1 via hnRNPH interactions. The Journal of neuroscience : the official journal of the Society for Neuroscience 2014; 34(33): 11048–11066.
    1. Nelson EC, Agrawal A, Heath AC, Bogdan R, Sherva R, Zhang B et al. Evidence of CNIH3 involvement in opioid dependence. Molecular psychiatry 2016; 21(5): 608–614.
    1. Greenwald MK, Steinmiller CL, Sliwerska E, Lundahl L, Burmeister M. BDNF Val(66)Met genotype is associated with drug-seeking phenotypes in heroin-dependent individuals: a pilot study. Addiction biology 2013; 18(5): 836–845.
    1. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, et al. Role of genotype in the cycle of violence in maltreated children, vol. 851e854. Science 297 (5582)2002.
    1. Weder N, Yang BZ, Douglas-Palumberi H, Massey J, Krystal JH, Gelernter J et al. MAOA genotype, maltreatment, and aggressive behavior: the changing impact of genotype at varying levels of trauma. Biological psychiatry 2009; 65(5): 417–424.
    1. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nature neuroscience 2005; 8(5): 594–596.
    1. Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS et al. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Archives of general psychiatry 2006; 63(12): 1396–1406.
    1. Tyndale RF, Sellers EM. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Therapeutic drug monitoring 2002; 24(1): 163–171.
    1. Tunbridge EM, Huber A, Farrell SM, Stumpenhorst K, Harrison PJ, Walton ME The role of catechol-O-methyltransferase in reward processing and addiction. CNS Neurol Disord Drug Targets 2012; 11(3): 306e323.
    1. Lobo MK, Nestler EJ. The striatal balancing act in drug addiction: distinct roles of direct and indirect pathway medium spiny neurons. Frontiers in neuroanatomy 2011; 5: 41.
    1. Samochowiec A, Grzywacz A, Kaczmarek L, Bienkowski P, Samochowiec J, Mierzejewski P et al. Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: family and case control study. Brain research 2010; 1327: 103–106.
    1. Song R, Zhang HY, Li X, Bi GH, Gardner EL, Xi ZX. Increased vulnerability to cocaine in mice lacking dopamine D3 receptors. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(43): 17675–17680.
    1. Szumlinski KK, Kalivas PW, Worley PF. Homer proteins: implications for neuropsychiatric disorders. Current opinion in neurobiology 2006; 16(3): 251–257.
    1. Stefaniuk M, Beroun A, Lebitko T, Markina O, Leski S, Meyza K et al. Matrix Metalloproteinase-9 and Synaptic Plasticity in the Central Amygdala in Control of Alcohol-Seeking Behavior. Biological psychiatry 2017; 81(11): 907–917.
    1. Samochowiec J, Ladehoff M, Pelz J, Smolka M, Schmidt LG, Rommelspacher H et al. Predominant influence of the 3’-region of dopamine D2 receptor gene (DRD2) on the clinical phenotype in German alcoholics. Pharmacogenetics 2000; 10(5): 471–475.
    1. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. Jama 2008; 299(11): 1291–1305.
    1. Schmitt JE, Neale MC, Fassassi B, Perez J, Lenroot RK, Wells EM et al. The dynamic role of genetics on cortical patterning during childhood and adolescence. Proceedings of the National Academy of Sciences of the United States of America 2014; 111(18): 6774–6779.
    1. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology 2014; 76 Pt B: 259–268.
    1. . , 2019, Accessed Date Accessed 2019 Accessed.
    1. Baby Connectome Project. , 2019, Accessed Date Accessed 2019 Accessed.
    1. Levenson JM, Sweatt JD. Epigenetic mechanisms: a common theme in vertebrate and invertebrate memory formation. Cellular and molecular life sciences : CMLS 2006; 63(9): 1009–1016.
    1. Champagne FA, Curley JP. How social experiences influence the brain. Current opinion in neurobiology 2005; 15(6): 704–709.
    1. Sun H, Maze I, Dietz DM, Scobie KN, Kennedy PJ, Damez-Werno D et al. Morphine epigenomically regulates behavior through alterations in histone H3 lysine 9 dimethylation in the nucleus accumbens. The Journal of neuroscience : the official journal of the Society for Neuroscience 2012; 32(48): 17454–17464.
    1. Govindan RM, Behen ME, Helder E, Makki MI, Chugani HT. Altered water diffusivity in cortical association tracts in children with early deprivation identified with Tract-Based Spatial Statistics (TBSS). Cerebral cortex (New York, NY : 1991) 2010; 20(3): 561–569.
    1. Sheridan MA, Fox NA, Zeanah CH, McLaughlin KA, Nelson CA 3rd. Variation in neural development as a result of exposure to institutionalization early in childhood. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(32): 12927–12932.
    1. Friedman EM, Karlamangla AS, Almeida DM, Seeman TE. Social strain and cortisol regulation in midlife in the US. Social science & medicine (1982) 2012; 74(4): 607–615.
    1. Karatsoreos IN, McEwen BS. Annual Research Review: The neurobiology and physiology of resilience and adaptation across the life course. Journal of Child Psychology and Psychiatry 2013; 54(4): 337–347.
    1. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science (New York, NY) 1997; 278(5335): 52–58.
    1. Wise RA. Roles for nigrostriatal--not just mesocorticolimbic--dopamine in reward and addiction. Trends in neurosciences 2009; 32(10): 517–524.
    1. Gianoulakis C Endogenous opioids and addiction to alcohol and other drugs of abuse. Current topics in medicinal chemistry 2004; 4(1): 39–50.
    1. Panlilio LV, Justinova Z. Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2018; 43(1): 116–141.
    1. Volkow ND, Baler RD. Addiction science: Uncovering neurobiological complexity. Neuropharmacology 2014; 76 Pt B: 235–249.
    1. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. The lancet Psychiatry 2016; 3(8): 760–773.
    1. Luscher C, Malenka RC. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling. Neuron 2011; 69(4): 650–663.
    1. Zweifel LS, Parker JG, Lobb CJ, Rainwater A, Wall VZ, Fadok JP et al. Disruption of NMDAR-dependent burst firing by dopamine neurons provides selective assessment of phasic dopamine-dependent behavior. Proceedings of the National Academy of Sciences of the United States of America 2009; 106(18): 7281–7288.
    1. Belin D, Jonkman S, Dickinson A, Robbins TW, Everitt BJ. Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behavioural brain research 2009; 199(1): 89–102.
    1. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. The American journal of psychiatry 2005; 162(8): 1403–1413.
    1. Perez de los Cobos J, Batlle F, Casas M. [Proposal for improving the integration of drug dependencies in psychiatric nosology]. Actas luso-espanolas de neurologia, psiquiatria y ciencias afines 1996; 24(2): 63–65.
    1. Geisler S, Wise RA. Functional implications of glutamatergic projections to the ventral tegmental area. Reviews in the neurosciences 2008; 19(4-5): 227–244.
    1. Koob GF, Le Moal M. Addiction and the brain antireward system. Annual review of psychology 2008; 59: 29–53.
    1. Stinus L, Le Moal M, Koob GF. Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 1990; 37(3): 767–773.
    1. Koob GF, Buck CL, Cohen A, Edwards S, Park PE, Schlosburg JE et al. Addiction as a stress surfeit disorder. Neuropharmacology 2014; 76 Pt B: 370–382.
    1. Kimura M, Satoh T, Matsumoto N. What does the habenula tell dopamine neurons? Nature neuroscience 2007; 10(6): 677–678.
    1. Hikosaka O. The habenula: from stress evasion to value-based decision-making. Nature reviews Neuroscience 2010; 11(7): 503–513.
    1. Matsumoto M, Hikosaka O. Lateral habenula as a source of negative reward signals in dopamine neurons. Nature 2007; 447(7148): 1111–1115.
    1. Metzger M, Bueno D, Lima LB. The lateral habenula and the serotonergic system. Pharmacology, biochemistry, and behavior 2017; 162: 22–28.
    1. Naqvi NH, Bechara A. The hidden island of addiction: the insula. Trends in neurosciences 2009; 32(1): 56–67.
    1. Bonson KR, Grant SJ, Contoreggi CS, Links JM, Metcalfe J, Weyl HL et al. Neural systems and cue-induced cocaine craving. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002; 26(3): 376–386.
    1. Pelchat ML, Johnson A, Chan R, Valdez J, Ragland JD. Images of desire: food-craving activation during fMRI. NeuroImage 2004; 23(4): 1486–1493.
    1. Wang Z, Faith M, Patterson F, Tang K, Kerrin K, Wileyto EP et al. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. The Journal of neuroscience : the official journal of the Society for Neuroscience 2007; 27(51): 14035–14040.
    1. Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y. Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. Neuroscience and biobehavioral reviews 2014; 38: 1–16.
    1. Niendam TA, Laird AR, Ray KL, Dean YM, Glahn DC, Carter CS. Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions. Cognitive, affective & behavioral neuroscience 2012; 12(2): 241–268.
    1. Bechara A, Damasio H, Damasio AR, Lee GP. Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. The Journal of neuroscience : the official journal of the Society for Neuroscience 1999; 19(13): 5473–5481.
    1. Damasio AR. The somatic marker hypothesis and the possible functions of the prefrontal cortex. Philosophical transactions of the Royal Society of London Series B, Biological sciences 1996; 351(1346): 1413–1420.
    1. Johnstone T, van Reekum CM, Urry HL, Kalin NH, Davidson RJ. Failure to regulate: counterproductive recruitment of top-down prefrontal-subcortical circuitry in major depression. The Journal of neuroscience : the official journal of the Society for Neuroscience 2007; 27(33): 8877–8884.
    1. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proceedings of the National Academy of Sciences of the United States of America 2011; 108(37): 15037–15042.
    1. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. The American journal of psychiatry 2001; 158(12): 2015–2021.
    1. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse (New York, NY) 1993; 14(2): 169–177.
    1. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Jayne M et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. The Journal of neuroscience : the official journal of the Society for Neuroscience 2007; 27(46): 12700–12706.
    1. George O, Sanders C, Freiling J, Grigoryan E, Vu S, Allen CD et al. Recruitment of medial prefrontal cortex neurons during alcohol withdrawal predicts cognitive impairment and excessive alcohol drinking. Proceedings of the National Academy of Sciences 2012; 109(44): 18156–18161.
    1. Kim HJ, Lee JH, Yun K, Kim JH. Alterations in Striatal Circuits Underlying Addiction-Like Behaviors. Molecules and cells 2017; 40(6): 379–385.
    1. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cerebral cortex (New York, NY : 1991) 2000; 10(3): 318–325.
    1. Fineberg NA, Potenza MN, Chamberlain SR, Berlin HA, Menzies L, Bechara A et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2010; 35(3): 591–604.
    1. Kober H, Lacadie CM, Wexler BE, Malison RT, Sinha R, Potenza MN. Brain Activity During Cocaine Craving and Gambling Urges: An fMRI Study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2016; 41(2): 628–637.
    1. Lee JH, Lim Y, Wiederhold BK, Graham SJ. A functional magnetic resonance imaging (FMRI) study of cue-induced smoking craving in virtual environments. Applied psychophysiology and biofeedback 2005; 30(3): 195–204.
    1. Risinger RC, Salmeron BJ, Ross TJ, Amen SL, Sanfilipo M, Hoffmann RG et al. Neural correlates of high and craving during cocaine self-administration using BOLD fMRI. NeuroImage 2005; 26(4): 1097–1108.
    1. Volkow ND, Wang GJ, Ma Y, Fowler JS, Wong C, Ding YS et al. Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. The Journal of neuroscience : the official journal of the Society for Neuroscience 2005; 25(15): 3932–3939.
    1. Khaled MA, Pushparaj A, Di Ciano P, Diaz J, Le Foll B. Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2014; 39(13): 3049–3058.
    1. McGlinchey EM, James MH, Mahler SV, Pantazis C, Aston-Jones G. Prelimbic to Accumbens Core Pathway Is Recruited in a Dopamine-Dependent Manner to Drive Cued Reinstatement of Cocaine Seeking. The Journal of neuroscience : the official journal of the Society for Neuroscience 2016; 36(33): 8700–8711.
    1. Yager LM, Garcia AF, Donckels EA, Ferguson SM. Chemogenetic inhibition of direct pathway striatal neurons normalizes pathological, cue-induced reinstatement of drug-seeking in rats. Addiction biology 2019; 24(2): 251–264.
    1. Piazza PV, Le Moal ML. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annual review of pharmacology and toxicology 1996; 36: 359–378.
    1. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS drugs 2005; 19(6): 517–537.
    1. Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP et al. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcoholism, clinical and experimental research 2002; 26(10): 1494–1501.
    1. Janes AC, Pizzagalli DA, Richardt S, de BFB, Chuzi S, Pachas G et al. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biological psychiatry 2010; 67(8): 722–729.
    1. Administration SAaMHS. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document 2018; HHS Publication No. (SMA) 18-5063FULLDOC. .
    1. National Academies of Sciences E, and Medicine Medications for Opioid Use Disorder Save Lives. The National Academies Press; 2019.
    1. Gowing L, Ali R, White JM. Opioid antagonists with minimal sedation for opioid withdrawal. The Cochrane Database of Systematic Reviews 2017; 5: Cd002021.
    1. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. The Cochrane Database of Systematic Reviews 2011; (9): Cd005031.
    1. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction (Abingdon, England) 2005; 100(8): 1090–1100.
    1. Smyth BP, Barry J, Keenan E, Ducray K. Lapse and relapse following inpatient treatment of opiate dependence. Irish medical journal 2010; 103(6): 176–179.
    1. Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction (Abingdon, England) 2010; 105(9): 1545–1554.
    1. Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. Journal of addictive diseases 2016; 35(1): 22–35.
    1. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. Journal of substance abuse treatment 2005; 28(4): 321–329.
    1. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug and alcohol dependence 2009; 105(1-2): 9–15.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews 2014; (2): Cd002207.
    1. McDermott KA, Griffin ML, Connery HS, Hilario EY, Fiellin DA, Fitzmaurice GM et al. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. The Journal of clinical psychiatry 2015; 76(2): 189–194.
    1. Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. The Cochrane Database of Systematic Reviews 2016; (5): Cd011117.
    1. Faggiano F V-TF, Versino E, Lemma P. . Methadone maintenance at different dosages for opioid dependence. . The Cochrane Database of Systematic Reviews 2003; 3(Cd002208).
    1. Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 2019; 393(10173): 778–790.
    1. Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. Journal of addiction medicine 2014; 8(5): 315–326.
    1. Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG et al. Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2016; 41(9): 2344–2351.
    1. Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. Journal of pain research 2015; 8: 859–870.
    1. Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. Jama 2016; 316(3): 282–290.
    1. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Archives of general psychiatry 2006; 63(2): 210–218.
    1. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (London, England) 2011; 377(9776): 1506–1513.
    1. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr. et al. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. The New England Journal of Medicine 2016; 374(13): 1232–1242.
    1. Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM et al. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. The American journal of psychiatry 2017; 174(5): 459–467.
    1. Vijay A, Morris E, Goldberg A, Petrulli J, Liu H, Huang Y, and Krishnan-Sarin S. Naltrexone occupancy at kappa opioid receptors investigated in alcoholics by PET occupancy at kappa opioid receptors investigated in alcoholics by PET J Nucl Med 2017; 58(1297).
    1. Weerts EM, Kim YK, Wand GS, Dannals RF, Lee JS, Frost JJ et al. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008; 33(3): 653–665.
    1. Lee JD, Nunes EV Jr., Novo P, Bachrach K, Bailey GL, Bhatt S et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet (London, England) 2018; 391(10118): 309–318.
    1. Tanum L, Solli KK, Latif ZE, Benth JS, Opheim A, Sharma-Haase K et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry 2017; 74(12): 1197–1205.
    1. Cushman P. Abstinence following detoxification and methadone maintenance treatment. The American Journal of Medicine 1978; 65(1): 46–52.
    1. Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of substance abuse treatment 2018; 85: 90–96.
    1. Nosyk B, Sun H, Evans E, Marsh DC, Anglin MD, Hser YI et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction (Abingdon, England) 2012; 107(9): 1621–1629.
    1. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clinical research ed) 2017; 357: j1550.
    1. Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO et al. A randomized controlled trial of interim methadone maintenance. Archives of general psychiatry 2006; 63(1): 102–109.
    1. Sigmon SC, Schwartz RP, Higgins ST. Buprenorphine for persons on waiting lists for treatment for opioid dependence. The New England Journal of Medicine 2017; 376(10): 1000–1001.
    1. Carroll KM, Weiss RD. The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review. The American journal of psychiatry 2017; 174(8): 738–747.
    1. Volkow ND, McLellan AT. Mitigation Strategies for Opioid Abuse. The New England Journal of Medicine 2016; 375(1): 96.
    1. Albert S, Brason FW 2nd, Sanford CK, Dasgupta N, Graham J, Lovette B. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain medicine (Malden, Mass) 2011; 12 Suppl 2: S77–85.
    1. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ (Clinical research ed) 2013; 346: f174.
    1. Freeman PR, Hankosky ER, Lofwall MR, Talbert JC. The changing landscape of naloxone availability in the United States, 2011 - 2017. Drug and alcohol dependence 2018; 191: 361–364.
    1. Murphy SM, Morgan JR, Jeng PJ, Schackman BR. Will converting naloxone to over-the-counter status increase pharmacy sales? Health services research 2019.
    1. Substance Abuse and Mental Health Services Administration SAaMHS. SAMHSA opioid overdose prevention toolkit. . HHS Publication (2016); (No. (SMA) 16-4742).
    1. D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. Jama 2015; 313(16): 1636–1644.
    1. Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and Treatment of Opioid Misuse and Addiction: A Review. JAMA Psychiatry 2019; 76(2): 208–216.
    1. Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addictive Behaviors 2017; 74: 63–66.
    1. Spoth R, Trudeau L, Shin C, Ralston E, Redmond C, Greenberg M et al. Longitudinal effects of universal preventive intervention on prescription drug misuse: three randomized controlled trials with late adolescents and young adults. American journal of public health 2013; 103(4): 665–672.
    1. Blanco C WM, Liu SM, Olfson M. . Towards a comprehensive developmental model of prescription opioid use disorder. . J Clin Psychiatry, in press.
    1. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Annals of Internal Medicine 2017; 167(5): 293–301.
    1. Collins FS, Koroshetz WJ, Volkow ND. Helping to End Addiction Over the Long-term: The Research Plan for the NIH HEAL Initiative. Jama 2018; 320(2): 129–130.
    1. Rasmussen K, White DA, Acri JB. NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2019; 44(4): 657–659.
    1. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature reviews Drug discovery 2009; 8(1): 41–54.
    1. Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 2016; 537(7619): 185–190.
    1. Levin FR, Bisaga A, Sullivan MA, Williams AR, Cates-Wessel K. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. The American journal on addictions 2016; 25(8): 603–609.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa